# Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

> **NCT01597258** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 2029 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Crizotinib (Xalkori)

## Key facts

- **NCT ID:** NCT01597258
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-29
- **Primary completion:** 2018-03-16
- **Final completion:** 2018-03-16
- **Target enrollment:** 2029 (ACTUAL)
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597258, "Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01597258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*